The Lonza Board of Directors has nominated Stephen Fry as an Independent Member of the Board, citing his extensive pharmaceutical industry experience and leadership in organizational transformation. Subject to election at the company's Annual General Meeting in May 2026, Fry will also join the People and Governance Committee and the Audit and Compliance Committee.
Fry spent over three decades at Eli Lilly and Company, where he held various international and executive leadership roles, culminating in his position as Executive Vice President and Chief Human Resources Officer for 12 years. In that role, he led large-scale organizational change, shaped high-performance cultures, and guided the company through significant transitions. He also serves as a Member of the Board of Trustees at the University of Indianapolis.
Jean-Marc Huet, Chairman of the Board at Lonza, commented: "Stephen brings extensive international experience, combined with a strong track record in organizational governance, succession planning and people strategy development, all of which form a valuable complementary fit with the capabilities of our other Board members. Stephen will play an important role in helping develop and embed our performance culture. This will support our ambition to attract and retain world-leading talent and bring our high-performing teams to the next level."
Lonza, the world's largest contract development and manufacturing organization (CDMO), generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025. The company works with pharma and biotech firms to bring treatments to patients globally. The nomination of Fry signals Lonza's focus on strengthening its organizational culture and talent strategy as it continues to scale. For more information about Lonza, visit www.lonza.com. The original press release can be viewed on www.newmediawire.com.
